MedPath

Effects of a Liquid Meal and Gut Hormones (GIP and GLP-2) on Bone Remodeling in Participants With Hypoparathyroidism.

Not Applicable
Completed
Conditions
Hypoparathyroidism
Registration Number
NCT03728959
Lead Sponsor
University of Copenhagen
Brief Summary

Hypoparathyroidism (hypoPT) is characterized by low levels of PTH.

In this study we will test the effects of a liquid meal on the bone remodeling in participants with hypoparathyroidism. Furthermore, we will test the effects of the gut hormones GIP and GLP-2.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
7
Inclusion Criteria
  • Age between 18 and 76
  • Hypoparathyroidism
Exclusion Criteria
  • Diabetes
  • Disease in the gastrointestinal tract
  • Antiosteoporotic drug
  • Long term steroid treatment (within the last 12 months)
  • Pregnancy

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Primary Outcome Measures
NameTimeMethod
Serum concentration of C-terminal telopeptide (CTX)-10 to 240 minutes

Marker of bone resorption, measured in serum

N-terminal propeptide of type 1 procollagen (P1NP)-10 to 240 minutes

Marker of bone formation, concentration measured in serum

Secondary Outcome Measures
NameTimeMethod
Glucose-dependent insulinotropic polypeptide (GIP)-10 to 240 minutes

Gut hormone, concentration measured in plasma

Glucagon-like peptide-2 (GLP-2)-10 to 240 minutes

Gut hormone, concentration measured in plasma

Glucagon-like peptide-1 (GLP-1)-10 to 240 minutes

Gut hormone, concentration measured in plasma

Glucose-10 to 240 minutes

Glucose concentration measured in serum

Insulin-10 to 240 minutes

Insulin concentration measured in serum

C-peptide-10 to 240 minutes

C-peptide concentration measured in serum

PTH-10 to 240 minutes

PTH concentration measured in serum

Trial Locations

Locations (1)

Hvidovre University Hospital

🇩🇰

Hvidovre, Denmark

Hvidovre University Hospital
🇩🇰Hvidovre, Denmark

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.